Equities

Arcticzymes Technologies ASA

Arcticzymes Technologies ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)17.34
  • Today's Change-1.36 / -7.27%
  • Shares traded1.22m
  • 1 Year change-45.39%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in NOK

The one analyst offering a 12 month price target expects Arcticzymes Technologies ASA share price to rise to 26.00 in the next year from the last price of 17.34.
High49.9%26.00
Med49.9%26.00
Low49.9%26.00

Earnings history & estimates in NOK

On Aug 22, 2024, Arcticzymes Technologies ASA reported 2nd quarter 2024 earnings of 0.05 per share.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate-6.06%
Arcticzymes Technologies ASA reported annual 2023 earnings of 0.37 per share on Feb 01, 2024.
Average growth rate-7.62%
More ▼

Revenue history & estimates in NOK

ArcticZymes Technologies ASA had 2nd quarter 2024 revenues of 26.50m. This missed the 29.50m consensus estimate of the 2 analysts following the company. This was 15.02% below the prior year's 2nd quarter results.
Average growth rate-1.11%
ArcticZymes Technologies ASA had revenues for the full year 2023 of 118.94m. This was 13.16% below the prior year's results.
Average growth rate+21.41%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.